Fresenius SE KGaAXSWX:FRE 71 Altman Z-Score is 1.45 as of Jun. 24, 2026, which is 21% above its 10-year median of 1.20. GuruFocus rates XSWX:FRE with a GF Score™ of 71/100 and a GF Value™ of CHF32.85 (Fairly Valued). The stock has 5 warning signs investors should review. Among 661 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 67.32% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.42 is in distress zone. This implies bankruptcy possibility in the next two years.
Fresenius SE KGaA has a Altman Z-Score of 1.45, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Fresenius SE KGaA's Altman Z-Score or its related term are showing as below:
XSWX:FRE'
s Altman Z-Score Range Over the Past 10 Years
Min: 0.59 Med: 1.2 Max: 2.03
Current: 1.42
During the past 13 years, Fresenius SE KGaA's highest Altman Z-Score was 2.03. The lowest was 0.59. And the median was 1.20.
Fresenius SE KGaA (XSWX:FRE) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Fresenius SE KGaA Altman Z-Score Related Terms
Fresenius SE KGaA Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: Altman Z-Score Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Fresenius SE KGaA's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.0597
+
1.4
*
0
+
3.3
*
0.0587
+
0.6
*
1.0419
+
1.0
*
0.5549
=
1.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Fresenius SE KGaA (XSWX:FRE) has a Altman Z-Score of 1.45 as of Jun. 24, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Fresenius SE KGaA and its competitors. This is 21% above median its historical median of 1.20. Over the past decade, Fresenius SE KGaA's Altman Z-Score has ranged from 0.59 to 2.03. According to the industry distribution chart, Fresenius SE KGaA ranks #445 out of 661 companies in the Healthcare Providers & Services industry, placing it in the top 67.3%.
Is Fresenius SE KGaA's Altman Z-Score too high?
Fresenius SE KGaA's current Altman Z-Score of 1.45 is 21% above median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 2.03. The Healthcare Providers & Services industry median Altman Z-Score is 2.38. Fresenius SE KGaA's value of 1.45 is 39.1% below this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #445 out of 661 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Altman Z-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #445 out of 661 companies for Altman Z-Score. This places Fresenius SE KGaA in the lower half of its industry. The industry median Altman Z-Score is 2.38. Fresenius SE KGaA's value of 1.45 is 39.1% below this benchmark. Historically, Fresenius SE KGaA's own Altman Z-Score has ranged from 0.59 to 2.03 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 2.38, Fresenius SE KGaA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.38, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current Altman Z-Score of 1.45 is 39.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current Altman Z-Score is 1.45, which is 21% above median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Fairly Valued. The stock's GF Value™ is CHF32.85, compared to a current price of CHF35.86 — trading 9.2% above its estimated fair value. The current Altman Z-Score is 1.45, which is 21% above median its 10-year median of 1.20 and 39.1% below the Healthcare Providers & Services industry median of 2.38. Fresenius SE KGaA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Altman Z-Score is 1.45 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF35.86 is trading 9.2% above its estimated GF Value™ of CHF32.85.
GuruFocus considers Fresenius SE KGaA to be Fairly Valued.
Key valuation signals for XSWX:FRE:
Altman Z-Score: 1.45 (21% above median its 10-year median of 1.20)
GF Value™: CHF32.85 vs. price of CHF35.86 (9.2% above fair value)
Industry Position: 39.1% below the Healthcare Providers & Services median (#445 of 661)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score
Get the complete analysis for XSWX:FRE
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
